JP6835332B2 - 動脈硬化を検出するための血中バイオマーカー - Google Patents
動脈硬化を検出するための血中バイオマーカー Download PDFInfo
- Publication number
- JP6835332B2 JP6835332B2 JP2018500165A JP2018500165A JP6835332B2 JP 6835332 B2 JP6835332 B2 JP 6835332B2 JP 2018500165 A JP2018500165 A JP 2018500165A JP 2018500165 A JP2018500165 A JP 2018500165A JP 6835332 B2 JP6835332 B2 JP 6835332B2
- Authority
- JP
- Japan
- Prior art keywords
- arteriosclerosis
- heavy chain
- myosin heavy
- antibody
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010003210 Arteriosclerosis Diseases 0.000 title claims description 121
- 208000011775 arteriosclerosis disease Diseases 0.000 title claims description 121
- 210000004369 blood Anatomy 0.000 title claims description 71
- 239000008280 blood Substances 0.000 title claims description 71
- 239000000090 biomarker Substances 0.000 title description 9
- 102100036639 Myosin-11 Human genes 0.000 claims description 105
- 101710115164 Myosin-11 Proteins 0.000 claims description 105
- 238000000034 method Methods 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 29
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 14
- 102000005604 Myosin Heavy Chains Human genes 0.000 claims description 7
- 108010084498 Myosin Heavy Chains Proteins 0.000 claims description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 27
- 108010029485 Protein Isoforms Proteins 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 238000011282 treatment Methods 0.000 description 17
- 210000004899 c-terminal region Anatomy 0.000 description 16
- 230000003902 lesion Effects 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000012276 Endovascular treatment Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000003018 immunoassay Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108010074051 C-Reactive Protein Proteins 0.000 description 9
- 102100032752 C-reactive protein Human genes 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 208000031481 Pathologic Constriction Diseases 0.000 description 8
- 210000002460 smooth muscle Anatomy 0.000 description 8
- 230000036262 stenosis Effects 0.000 description 8
- 208000037804 stenosis Diseases 0.000 description 8
- 102000003505 Myosin Human genes 0.000 description 7
- 108060008487 Myosin Proteins 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 210000004897 n-terminal region Anatomy 0.000 description 7
- 238000002552 multiple reaction monitoring Methods 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 208000007474 aortic aneurysm Diseases 0.000 description 5
- 239000010419 fine particle Substances 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000003118 sandwich ELISA Methods 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 3
- 238000001790 Welch's t-test Methods 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000007211 cardiovascular event Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 200000000007 Arterial disease Diseases 0.000 description 2
- 102100038196 Chitinase-3-like protein 1 Human genes 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- 206010060874 Aortic rupture Diseases 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 101001000104 Homo sapiens Myosin-11 Proteins 0.000 description 1
- 208000008952 Iliac Aneurysm Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 201000008982 Thoracic Aortic Aneurysm Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000003457 familial thoracic 1 aortic aneurysm Diseases 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 102000045989 human MYH11 Human genes 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010072415 tumor necrosis factor precursor Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Description
<材料及び方法>
動脈硬化の進行により冠動脈や大動脈、末梢血管に狭窄、梗塞、瘤等の動脈疾患を発症し、カテーテル治療又はステント治療を受けた患者を対象とした。各患者における動脈硬化病変の存在は、血管造影(狭窄・梗塞の確認)又はCT(石灰化の確認)により確認した。動脈硬化性が確定できない患者は除外した。インターベンション前又はインターベンション直後〜数日以内に各患者から採取した血液より血漿を分離し、血漿中のミオシン重鎖11(MYH11)レベルを血中MYH11レベルとして測定した。陰性対照の正常血漿サンプル50名分(コーカサス人、ヒスパニック系、黒人を含む)は市販品を購入して使用した。
<結果>
図1−1は、正常50名及び動脈硬化を有する患者計78名の、血中MYH11レベルの測定結果である。正常群と比較して、動脈硬化患者群では明らかに血中MYH11が高値であった。
<材料及び方法>
動脈硬化検体として、上記1.の動脈硬化患者血漿のうち、PCI適用患者29名(69.5±1.4歳、BMI: 22.4±0.5、男:女=26:3)及びEVT適用患者17名(72.4±1.4歳、BMI: 23.6±1.1、男:女=13:4)に由来する血漿を用いた。正常検体として、動脈硬化及びそのリスクファクターのない日本人健常者40名(70.4±0.6歳、BMI: 23.3±0.2、男:女=33:7)の血漿を用いた。サンドイッチELISAは、上記1.と同じくCUSABIO社のELISAキットを用いて行なった。
図3−1は、PCI適用動脈硬化患者及びEVT適用動脈硬化患者について、正常日本人40名と血中MYH11レベルの測定値を対比した結果である。図3−2は、各動脈硬化患者群の血中MYH11レベルによる検出能をROC解析により評価した結果である。日本人健常者との対比でも、動脈硬化患者の血中MYH11レベルは有意に高く、AUCも0.9を超える高い値であった。
(1) CRPとの診断性能の比較
C-reactive protein (CRP)は心血管イベント予測のマーカーであり、動脈硬化でも血中CRP値が上昇することが知られている(Blankengerg S, et al., Circulation 2010; 121: 2388-97)。血中ミオシン重鎖11レベルによる動脈硬化の診断性能について評価するため、上記2.と同じ動脈硬化患者(PCI患者29名、EVT患者17名)及び日本人健常者の血漿中CRPレベルを調べた。
喫煙は主要な動脈硬化リスクファクターの1つであり、喫煙と動脈硬化は相関することが知られている。日本人健常者、PCI患者、EVT患者の血漿中MYH11レベルとブリンクマンインデックス(1日の喫煙本数×喫煙年数)との相関を調べたところ、図6に示す通り、両者の間には相関があった。健常であっても動脈硬化は加齢とともにゆるやかに進行することから、健常者集団の中にはごく軽度の動脈硬化を有する者も含まれていると考えられる。PCI患者及びEVT患者は、治療処置が必要なレベルの動脈硬化重症例である。図6に示したデータは、軽度の動脈硬化でも血中MYH11レベルによって検出し得ることを示唆している。
<材料及び方法>
(1)抗体固定化微粒子の調製
抗体を固相する磁性微粒子(Dynabeads(登録商標) M-280 Tosylactivated; Thermo Fisher Scientific)をプロトコルに記載されている緩衝液にて懸濁し、Anti MYH11 Human(HPA015310; コスモバイオ)を混合させ、37℃で17時間抗体を固定化した。抗体固定化後、10%のBlockmaster CE510(JSR)を含む0.05 mol/L Tris-HCl緩衝液(pH8.0)中に抗体固定化微粒子を懸濁し、37℃で5時間インキュベートしてブロッキングを行い、0.2 mg/mL beadsの抗MYH11抗体固定化磁性微粒子(A)を得た。
MYH11のターゲットペプチドであるMyosin Motor構造由来ペプチド(N末端側構造由来のペプチドとして; ALELDPNLYR; 配列番号4の760番〜769番残基の領域)及びCoiled-coil構造由来ペプチド(C末端側構造由来のペプチドとして; LEVNMQALK; 配列番号4の1572番〜1580番残基の領域)を選定し、安定同位体標識(13C及び15N)したペプチドを合成した(AQUAペプチド; Sigma-Aldrich)。
上記1.で用いた患者検体のうち、血漿中MYH11レベルが比較的高い値で検出された患者数名の血漿をプールした検体を患者検体として用いた。陰性対照の健常者検体には、日本人健常者6名分のプール血漿検体を用いた。
得られたMRM測定用サンプル(D)を、三連四重極型質量分析装置QTRAP 5500(AB SCIEX)に供して、二つのペプチド、MYH11-Myosin MotorペプチドおよびMYH11-Coiled-coilペプチドの測定を行った。両ペプチドを検出、定量するためのMRMメソッドを表1に示した。測定結果はSkylineソフトウェアにて解析した。定量用チャネル(Quantitation)におけるMRMシグナルの溶出時間が、対応する確認用チャネル(Verification)のシグナルと一致していることを確認することで、シグナルの信頼性を評価した。次に、各ペプチドの定量用チャネルにおいて、Heavyペプチドに対するLightペプチドのピーク面積比を算出することで、分析サンプル中に含まれる両ペプチドのモル濃度を計算した。
内部標準ペプチドを指標に、検体中にあるMYH11について、二つのターゲットペプチドの定量用チャネルよりモル濃度を測定した。結果を図7に示す。比較対象とした健常者検体では、どちらのペプチドも検出限界以下であった。一方、動脈硬化検体では、MYH11のC末端側構造に由来するペプチドが非常に高値で検出され、健常者よりも有意に高いことが判明した。N末端側構造に由来するペプチドは、C末端側構造に由来するペプチドと比べると低値ではあるものの、やはり同様に健常者と比較して動脈硬化検体の方が有意に高いことが判明した。
PCI又はEVTを受けた患者の術後経過を観察したところ(観察期間1〜2.5年)、3名の死亡例があった。インターベンション直後の死亡ではないことから、インターベンションの手技による死亡ではないことは明らかである。
1.EVTインターベンション後64日後 感染症により死亡
2.EVTインターベンション後294日後 感染症により死亡
3.PCIインターベンション後163日後 播種性血管内凝固症候群(DIC)により死亡
Claims (2)
- 動脈硬化の検出を補助する方法であって、被検者から分離された血液試料中のミオシン重鎖11レベルを測定することを含み、健常者よりも高いミオシン重鎖11レベルは、当該被検者が動脈硬化を有することの指標となる、方法。
- 抗ミオシン重鎖11抗体又はその抗原結合性断片を含む、血液試料中のミオシン重鎖11レベルに基づき動脈硬化を検出するためのキットであって、健常者よりも高い血中ミオシン重鎖11レベルが動脈硬化の存在の指標となる、キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016026494 | 2016-02-16 | ||
JP2016026494 | 2016-02-16 | ||
PCT/JP2017/005565 WO2017141980A1 (ja) | 2016-02-16 | 2017-02-15 | 動脈硬化を検出するための血中バイオマーカー |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2017141980A1 JPWO2017141980A1 (ja) | 2018-12-06 |
JP6835332B2 true JP6835332B2 (ja) | 2021-02-24 |
Family
ID=59625896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018500165A Active JP6835332B2 (ja) | 2016-02-16 | 2017-02-15 | 動脈硬化を検出するための血中バイオマーカー |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190049464A1 (ja) |
EP (1) | EP3418747B1 (ja) |
JP (1) | JP6835332B2 (ja) |
CN (1) | CN108700597A (ja) |
WO (1) | WO2017141980A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110082535B (zh) * | 2019-03-29 | 2022-06-10 | 南方医科大学南方医院 | 用于诊断慢性冠心病的分子标志物myh11及其应用 |
JP7496992B2 (ja) | 2019-11-29 | 2024-06-10 | 公立大学法人横浜市立大学 | 動脈硬化病変の検出方法、検出試薬及び検出キット |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0465652B1 (en) * | 1989-03-28 | 1995-06-07 | Yamasa Shoyu Kabushiki Kaisha | Antibody against heavy chain of smooth muscle myosin |
AU691675B2 (en) * | 1994-10-25 | 1998-05-21 | Yamasa Corporation | Antibody reagent for detecting dissecting aortic aneurysm and use thereof |
JP3981147B2 (ja) * | 1996-02-19 | 2007-09-26 | ヤマサ醤油株式会社 | 消化器疾患用抗体試薬 |
US20020015950A1 (en) * | 1999-07-07 | 2002-02-07 | Karen Anne Jones | Atherosclerosis-associated genes |
CN1321666A (zh) * | 2000-04-29 | 2001-11-14 | 上海博德基因开发有限公司 | 一种新的多肽——人肌球蛋白重链11和编码这种多肽的多核苷酸 |
EP1666611A1 (en) * | 2004-12-06 | 2006-06-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Diagnosis of arterial diseases by identification of a mutation in the MYH11 gene or protein |
JP5415946B2 (ja) * | 2007-06-18 | 2014-02-12 | 積水メディカル株式会社 | 新規な動脈硬化性疾患マーカー |
CN101125146B (zh) * | 2007-07-02 | 2011-05-04 | 中国药科大学 | 一种防治炎症相关心脑血管疾病的药物靶标及其抑制剂 |
US20120316211A1 (en) * | 2011-05-11 | 2012-12-13 | The Board or Regents of the University of Texas System | Diagnostic Methods for Assessing Risk of Chagas Disease and Heart Failure |
-
2017
- 2017-02-15 JP JP2018500165A patent/JP6835332B2/ja active Active
- 2017-02-15 CN CN201780011828.9A patent/CN108700597A/zh active Pending
- 2017-02-15 US US16/077,704 patent/US20190049464A1/en not_active Abandoned
- 2017-02-15 WO PCT/JP2017/005565 patent/WO2017141980A1/ja active Application Filing
- 2017-02-15 EP EP17753236.3A patent/EP3418747B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3418747A4 (en) | 2019-07-31 |
US20190049464A1 (en) | 2019-02-14 |
JPWO2017141980A1 (ja) | 2018-12-06 |
EP3418747B1 (en) | 2022-01-12 |
EP3418747A1 (en) | 2018-12-26 |
WO2017141980A1 (ja) | 2017-08-24 |
CN108700597A (zh) | 2018-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6639392B2 (ja) | 胎盤成長因子2の選択的測定法 | |
US20230221339A1 (en) | Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-andrenomedullin binder for use in therapy or prevention of dementia | |
JP6835332B2 (ja) | 動脈硬化を検出するための血中バイオマーカー | |
US20190011463A1 (en) | Diagnosis of unstable angina | |
CN111579784B (zh) | 以dhps基因作为指标使用的动脉硬化及癌的检测方法 | |
WO2007072896A1 (ja) | 急性冠症候群の予後予測方法 | |
JP2024511867A (ja) | 子宮内膜症の非侵襲的診断のための血液バイオマーカーとしてのpsp94 | |
JP2023548961A (ja) | 急性冠症候群の新規バイオマーカー | |
JP7496992B2 (ja) | 動脈硬化病変の検出方法、検出試薬及び検出キット | |
JP5229866B2 (ja) | 大腸癌、動脈硬化症、又はメタボリックシンドロームの検出方法 | |
CN116699141A (zh) | 混合检测PCT和Presepsin的试剂盒、方法以及应用 | |
WO2019212364A1 (en) | Test for heart failure | |
JP6555711B2 (ja) | 非解離性大動脈瘤の疾患活動性の判定方法 | |
JP2020020755A (ja) | 肝硬変の診断方法、非アルコール性脂肪肝炎及び肝細胞がんの合併症の診断方法並びに非アルコール性脂肪肝炎及び食道胃静脈瘤の合併症の診断方法 | |
JP7485273B2 (ja) | 抗vegf-a抗体による癌に対する治療応答性を予測又は決定するための方法 | |
US20230093265A1 (en) | New method and compound for prostate cancer diagnosis | |
WO2021253335A1 (zh) | 抗可溶性cd14亚型抗体、试剂盒及其应用 | |
JP2024060569A (ja) | 本態性高血圧症を検出するためのバイオマーカー、それを用いた検出方法及び検出試薬 | |
KR20180041466A (ko) | 코어-푸코실화된 알파-페토프로테인에 특이적으로 결합하는 항체 및 그의 용도 | |
JPWO2016140210A1 (ja) | 膵臓機能異常の検出方法及び検出用キット | |
JP2024070581A (ja) | Als検査用バイオマーカー及び検査方法 | |
JP5429723B2 (ja) | 大腸癌、動脈硬化症、又はメタボリックシンドロームの検出方法 | |
JP2024045038A (ja) | 胃癌の高度リンパ節転移を検出するためのバイオマーカー、それを用いた検出方法及び検出試薬 | |
JP2023156159A (ja) | がんリスクの試験方法 | |
EP4126935A1 (en) | Type xix collagen assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180810 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200123 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200828 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201215 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201228 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210120 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6835332 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |